<DOC>
	<DOC>NCT02715479</DOC>
	<brief_summary>The purpose of this study is to evaluate how BMS955176 affects pharmacokinetics (PK) of Dolutegravir (DTG) and also how DTG administration affects the PK of BMS955176</brief_summary>
	<brief_title>A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>1. Signed Informed Consent 2. Target population: Healthy males and females. 3. Women of child bearing potential (WOCBP) with negative serum pregnancy test 4. Women must not be breastfeeding 5. Men and WOCBP must agree to follow instructions for contraception 1. History of any chronic or acute illness, gastrointestinal disease, GI surgery, cardiac disease or clinically significant cardiac arrhythmia 2. History of frequent headaches or acute diarrhoea. 3. Any major surgery within 4 weeks of study drug administration 4. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population 5. History of allergy to HIV maturation and integrase inhibitors,or related compounds 6. History of smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>